Masaya Hattori
机构：Aichi Cancer Center · ORCID：0000-0002-0935-9269
发表论文 227 篇 · 总被引 9960 次 · h-index 31
代表论文
- Datopotamab Deruxtecan Versus Chemotherapy in Previously Treated Inoperable/Metastatic Hormone Receptor–Positive Human Epidermal Growth Factor Receptor 2–Negative Breast Cancer: Primary Results From TROPION-Breast01 (2024 · Journal of Clinical Oncology · 被引 167)
- VP1-2025: Datopotamab deruxtecan (Dato-DXd) vs chemotherapy (CT) in previously-treated inoperable or metastatic hormone receptor-positive, HER2-negative (HR+/HER2–) breast cancer (BC): Final overall survival (OS) from the phase III TROPION-Breast01 trial (2025 · Annals of Oncology · 被引 18)
- Safety and pharmacokinetics of vepdegestrant in Japanese patients with ER+ advanced breast cancer: a phase 1 study (2024 · International Journal of Clinical Oncology · 被引 9)
- Datopotamab deruxtecan (Dato-DXd) vs chemotherapy (CT) in previously treated inoperable or metastatic hormone receptor-positive, HER2-negative (HR+/HER2–) breast cancer (BC): Patient-reported outcomes (PROs) from the TROPION-Breast01 study. (2024 · Journal of Clinical Oncology · 被引 7)
- Role of circulating tumor cells in breast cancer (2024 · Breast Cancer · 被引 3)
- A retrospective multi-center cohort study investigating safety of sentinel lymph node biopsy for axillary staging in clinical T3-4c breast cancer (2025 · Breast Cancer · 被引 2)